Ignite Creation Date:
2025-12-25 @ 4:52 AM
Ignite Modification Date:
2026-03-01 @ 12:34 PM
Study NCT ID:
NCT02853318
Status:
COMPLETED
Last Update Posted:
2021-10-06
First Post:
2016-07-29
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Sponsor:
Roswell Park Cancer Institute
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-09-01
Start Date Type:
ACTUAL
Primary Completion Date:
2019-06-27
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-06-30
Completion Date Type:
ACTUAL
First Submit Date:
2016-07-29
First Submit QC Date:
None
Study First Post Date:
2016-08-02
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2020-08-28
Results First Submit QC Date:
None
Results First Post Date:
2020-11-06
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-09-16
Last Update Post Date:
2021-10-06
Last Update Post Date Type:
ACTUAL